Blood test to track giant cell bone tumors
Part of Cancer clinical trials.
This study uses a simple blood test (TRACP-5b) to help diagnose and monitor giant cell tumors of the bone. Researchers want to see if this test can better track how the tumor responds to treatment or comes back over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of giant cell tumor of bone (a type of bone tumor)
- You are 18 years or older
- You are either newly diagnosed or being followed after previous treatment
- You can understand the study and give written permission to participate
- You do not have other bone or metabolic diseases that could interfere with the blood test results
- You can attend routine follow-up appointments as scheduled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests narlumosbart (JMT103) to see if it works and is safe for people with giant cell tumor of bone that cannot be fully removed with surgery. If you qualify, you may be compared against another treatment and monitored closely for side effects and tumor response.
This study looks at whether taking a bone-strengthening medicine called a bisphosphonate after surgery can lower the chance that a giant cell tumor in a leg or arm comes back. It may help prevent recurrence after removing the tumor from the bone.
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
This study checks if a new blood test (PanTum Detect) can find cancer or pre-cancer. It compares results in people who may have cancer and in healthy people, using a PET/CT scan as a reference. This could lead to a simpler way to detect cancer early.
This trial studies a blood test that looks for circulating tumor markers in people with any type of invasive cancer (newly diagnosed or suspected). The goal is to see if markers in the blood can help monitor the cancer and guide treatment.
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
Hear when a new Giant Cell Tumor of Bone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.